BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 29676521)

  • 1. Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling.
    Yokoyama Y; Sekiguchi A; Fujiwara C; Uchiyama A; Uehara A; Ogino S; Torii R; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2018 Oct; 70(10):1661-1672. PubMed ID: 29676521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis.
    Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI
    Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chitturi P; Xu S; Ahmed Abdi B; Nguyen J; Carter DE; Sinha S; Arora R; Biernaskie J; Stratton RJ; Leask A
    Ann Rheum Dis; 2023 Sep; 82(9):1191-1204. PubMed ID: 37328193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apelin/APJ signaling suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model.
    Yamazaki S; Sekiguchi A; Uchiyama A; Fujiwara C; Inoue Y; Yokoyama Y; Ogino S; Torii R; Hosoi M; Akai R; Iwawaki T; Ishikawa O; Motegi SI
    Sci Rep; 2020 Jan; 10(1):1349. PubMed ID: 31992828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis.
    Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q
    J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress.
    Sekiguchi A; Motegi SI; Fujiwara C; Yamazaki S; Inoue Y; Uchiyama A; Akai R; Iwawaki T; Ishikawa O
    J Dermatol Sci; 2019 Oct; 96(1):8-17. PubMed ID: 31447184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.
    Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H
    J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
    Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
    Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
    Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.
    Piera-Velazquez S; Makul A; Jiménez SA
    Arthritis Rheumatol; 2015 Oct; 67(10):2749-58. PubMed ID: 26096997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
    Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
    J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
    Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
    Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
    Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
    Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.
    Zhang Y; Pötter S; Chen CW; Liang R; Gelse K; Ludolph I; Horch RE; Distler O; Schett G; Distler JHW; Dees C
    Ann Rheum Dis; 2018 May; 77(5):744-751. PubMed ID: 29431122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.